Overexpression of CYP1A1 can disrupt the estrogen signaling pathway and diminish the ability of 17β-estradiol to protect against hepatic steatosis, which is marked by the buildup of TG (17), a pathological feature of MASLD (35). This evidence concerns the gene CYP1A1 and fatty liver disease.